MedMira Inc. announced the appointment of Dr. Sam Ratnam as the company's director of Scientific & Regulatory Affairs. Dr. Ratnam brings over 40 years of experience in public health, regulatory affairs and has been the principal in a number of important regulations set forward by the health authorities such as the guidelines on Syphilis, Hepatitis C and HPV. His invaluable expertise and intrinsic knowledge of the regulatory and clinical trial framework in Canada and the United States, will provide the Company even further momentum to push forward on its current and future applications.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.075 CAD | 0.00% | 0.00% | -31.82% |
Apr. 02 | MedMira Inc. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2024 | CI |
Mar. 27 | Samsung Pay to stop working with Russia's Mir payment system from April 3 | RE |
1st Jan change | Capi. | |
---|---|---|
-31.82% | 38.45M | |
+8.07% | 219B | |
+6.59% | 183B | |
+11.26% | 133B | |
+26.57% | 108B | |
+0.65% | 63.06B | |
+13.35% | 52.02B | |
-0.62% | 48.2B | |
-0.93% | 40.37B | |
+11.54% | 39.35B |
- Stock Market
- Equities
- MIR Stock
- News MedMira Inc.
- MedMira Inc. Appoints Sam Ratnam as Director of Scientific & Regulatory Affairs